rs11660725 - ASXL3 - NOL4

Magnitude 2.2 · 1 study on file

Reported associations

  • Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction - Unknown journal (n.d.) · Unknown authors · PubMed 38839884

    ABSTRACT: Restless legs syndrome (RLS) affects up to 10% of older adults. Their healthcare is impeded by delayed diagnosis and insufficient treatment. To advance disease prediction and find new entry points for therapy, we performed meta-analyses of genome-wide association studies in 116,647 individuals with RLS (cases) and 1,546,466 controls of European ancestry. The pooled analysis increased the number of risk loci eightfold to 164, including three on chromosome X. Sex-specific meta-analyses revealed largely overlapping genetic predispositions of the sexes (rg = 0.96). Locus annotation prioritized druggable genes such as glutamate receptors 1 and 4, and Mendelian randomization indicated RLS as a causal risk factor for diabetes. Machine learning approaches combining genetic and nongen


Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • Restless legs syndrome genetic risk Moderate

    rs11660725 is a significant genome-wide associated variant for restless legs syndrome susceptibility

    Discuss this genetic finding and potential RLS screening with healthcare provider

Screening

  • Restless legs syndrome symptoms Moderate

    Genetic risk from rs11660725 warrants clinical attention to RLS presentation

    Monitor for evening or night-time leg discomfort, restlessness, or sleep disruption